Audited Financial Results for the quarter and year ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr Lalchandani Labs reported FY26 revenue from operations of Rs. 418.58 lacs, down about 6% from Rs. 445.38 lacs in FY25. Total expenses rose to Rs. 470.05 lacs from Rs. 418.04 lacs, pushing the company to a pre-exceptional loss of Rs. 51.31 lacs versus a profit of Rs. 28.08 lacs last year. A one-time settlement (OTS) gain of Rs. 61.08 lacs from unsecured loan waivers with banks/NBFCs helped flip the bottom line to a small reported net profit of Rs. 6.35 lacs (vs Rs. 3.11 lacs). Net worth surged to Rs. 1,413.34 lacs from Rs. 995.71 lacs via fresh share capital, while operating cash flow swung sharply negative to Rs. (76.46) lacs from a positive Rs. 44.30 lacs. The auditor issued a qualified opinion flagging NPA status with lenders, defaults on loan repayments, unpaid PF/ESIC/TDS dues, unprovided gratuity liability, and absence of balance confirmations and doubtful debt provisions.
Shareholders should note that the reported profit is almost entirely due to a one-time debt waiver gain and not from operations, which are loss-making. The qualified auditor opinion, NPA loan status, unpaid statutory dues, and negative operating cash flow point to serious financial stress and heightened going-concern risk, which could weigh negatively on the stock and signal the need for the recent Rights Issue proceeds to shore up the balance sheet.